News | Brachytherapy Systems, Women's Healthcare | May 01, 2017

Australia's Monash Cancer Centre Treats First Early-Stage Breast Cancer Patient With Xoft System

Cancer center in Melbourne is the first in the country to install electronic brachytherapy system

Australia's Monash Cancer Centre Treats First Early-Stage Breast Cancer Patient With Xoft System

May 1, 2017 — iCAD Inc. announced the first early-stage breast cancer patient was treated in Australia with intraoperative radiation therapy (IORT) using the Xoft Axxent Electronic Brachytherapy (eBx) System. The patient was treated at Monash Cancer Centre, a partnership between Peter MacCallum Cancer Centre and Monash Health, in Melbourne, Australia.

In March 2017, Monash Cancer Centre became the first medical center in Australia to adopt the Xoft System through iCAD’s local distribution partner, Regional Health Care Group Pty Ltd. The system is U.S. Food and Drug Administration (FDA)-cleared, CE marked, entered in the Australian Register of Therapeutic Goods (ARTG), and licensed in a growing number of countries for the treatment of cancer anywhere in the body. This includes early-stage breast cancer, non-melanoma skin cancer and gynecological cancer.

For the treatment of early-stage breast cancer, IORT with the Xoft System allows radiation oncologists and breast surgeons to work together to administer one precise, concentrated dose of radiation to a tumor site at the time of lumpectomy. IORT with the Xoft System can be completed in as little as eight minutes, making it possible to replace six to eight weeks of traditional radiation therapy with a single treatment.

The system’s miniaturized X-ray source can be inserted into a variety of applicators that are specifically designed for certain clinical indications. Monash Cancer Centre will offer the complete suite of Xoft System applicators used to deliver IORT, skin eBx, endometrial and cervical cancer radiation treatment.

“Our adoption of the Xoft System underscores our commitment to providing optimal quality of care to our patients and we are proud to be the first to offer this technology to patients in Australia in the context of an international clinical trial,” said Steven David, M.D., MBBS, FRANZCR, radiation oncologist, Moorabbin Campus director, Peter MacCallum Cancer Centre. “In our detailed review of the range of available radiation therapy solutions, the Xoft System’s distinguished versatility across a variety of clinical applications, mobility and unique patient benefits made it the pre-eminent solution for our practice.”

Monash Cancer Centre is the second international site to participate in iCAD’s clinical trial evaluating the Xoft System for the treatment of early-stage breast cancer, called the ExBRT trial.

“Intraoperative radiotherapy will offer women with early-stage breast cancer another therapeutic option, and, we believe, a better patient experience with less treatment morbidity, and a more rapid return to normal activity. As well as our current commitment to the study, we hope the breast service and other Monash Cancer Centre tumor services, will be able to contribute to understanding the use of this technology in other disease types and stages,” said Jane Fox, M.D., director, breast services, Monash Health. “We are encouraged by the research to date as the global community of treatment centers continues to provide appropriate patients with the unique option to complete a full dose of radiation therapy in a single treatment.”

Monash Cancer Centre at Moorabbin Hospital is a key service of Monash Health, the largest health service in the state of Victoria. The Monash Cancer Centre provides cancer treatment for the more than 1.5 million residents of southern Melbourne.

For more information: www.xoftinc.com

Related Content

SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
RaySearch Releases New Version of RayCare OIS
Technology | Oncology Information Management Systems (OIMS) | July 13, 2018
RaySearch has released RayCare 2A, the latest version of its flagship oncology information system (OIS). RayCare is...
Breast Cancer Follow-up Imaging Varies Widely
News | Breast Imaging | July 13, 2018
July 13, 2018 — Follow-up imaging for women...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
Invision Diagnostics Installs VolparaEnterprise Software to Enhance Mammography Image Quality
News | Mammography | July 11, 2018
Invision Diagnostics, a provider of mobile mammography services across North and South Carolina, announced that it is...
Breast Cancer Studies Ignore Race, Socioeconomic Factors
News | Women's Health | July 11, 2018
A new commentary appearing in the July issue of Cancer Causes & Control points to evidence that social factors help...
Bruce Power Joins Forces With ITM to Supply Lutetium-177 for Cancer Therapy
News | Radiation Therapy | July 11, 2018
Canadian nuclear power company Bruce Power and German-based Isotope Technologies Garching (ITG) signed an agreement to...
MedStar Georgetown University Hospital Now Clinical With RayStation and Hyperscan
News | Treatment Planning | July 05, 2018
MedStar Georgetown University Hospital in Washington D.C., has begun patient treatments using the RayStation treatment...
Jeffrey Hoffmeister, M.D.

Jeffrey Hoffmeister, M.D.

Feature | Breast Imaging | July 05, 2018 | By Jeffrey Hoffmeister, M.D.
When women reach age 40, an annual mammogram becomes a necessary part of their healthcare ritual — regardless if they...
Northern Centre for Cancer Care (NCCC)

Northern Centre for Cancer Care (NCCC).

Sponsored Content | Case Study | Radiation Therapy | July 05, 2018
Established in 2009, Northern Centre for Cancer Care (NCCC) is the largest center of its kind in the north of England....
Overlay Init